Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), sold 93,290,722 shares at a price of $1009.00 each on November 11, 2025, totaling $94,130.34 million. Following this transaction, Lilly Endowment Inc retains 93,290,722 shares of the company.
Eli Lilly & Co is a major player in the pharmaceuticals industry, headquartered in Indianapolis, Indiana, with a workforce of 47,000 employees. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products, including cardiometabolic health, oncology, immunology, and neuroscience products. Key offerings include Humalog, Jardiance, and Trulicity, among others.
As of November 13, 2025, Eli Lilly reported a market capitalization of $962.2 billion, a P/E ratio of 52.26, and an EPS of 20.45. The company's dividend yield stands at 59.0%. Upcoming earnings are projected for August 4, 2026, with an EPS estimate of $7.70 and revenue expectations of $17.9 billion.
While insider selling can occur for various reasons, it is important for investors to consider such transactions in the context of broader insider activity, rather than as isolated events. Regulatory requirements mandate that these transactions be reported to the SEC, providing transparency into the actions of company executives and board members.